- |||||||||| lapatinib / Generic mfg., temozolomide / Generic mfg.
Trial completion, Trial primary completion date: Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma (clinicaltrials.gov) - Sep 28, 2018 P2, N=58, Completed, N=70 --> 6 | Recruiting --> Terminated; It ended early because it would not be possible to meet the target number. Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Jul 2018
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma (clinicaltrials.gov) - Sep 19, 2017 P2, N=97, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> May 2017 Active, not recruiting --> Completed | N=140 --> 97 | Trial primary completion date: Dec 2010 --> Oct 2015
- |||||||||| Phase classification: Proton Radiation Therapy for Spinal Tumors (clinicaltrials.gov) - Feb 11, 2017
P=N/A, N=0, Withdrawn, Active, not recruiting --> Completed | Phase classification: PN/A --> P Phase classification: P2 --> P=N/A
- |||||||||| Enrollment change, Trial withdrawal, Trial primary completion date: Proton Radiation Therapy for Spinal Tumors (clinicaltrials.gov) - Aug 25, 2015
P2, N=0, Withdrawn, Active, not recruiting --> Completed N=34 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: May 2025 --> Aug 2015
- |||||||||| lapatinib / Generic mfg., temozolomide / Generic mfg.
Trial primary completion date: Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma (clinicaltrials.gov) - Dec 10, 2014 P2, N=50, Active, not recruiting, Recruiting --> Completed Trial primary completion date: Jan 2015 --> Jan 2016
- |||||||||| Trial primary completion date: Proton Radiation Therapy for Spinal Tumors (clinicaltrials.gov) - Sep 28, 2014
P2, N=34, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2012 --> Dec 2014 Trial primary completion date: May 2024 --> May 2025
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment change: Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma (clinicaltrials.gov) - Apr 20, 2014 P2, N=140, Active, not recruiting, N=24 --> 31 N=97 --> 140
- |||||||||| carboplatin / Generic mfg., temozolomide / Generic mfg., vincristine / Generic mfg.
Enrollment closed: Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma (clinicaltrials.gov) - Oct 24, 2013 P=N/A, N=66, Active, not recruiting, Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- |||||||||| carboplatin / Generic mfg., temozolomide / Generic mfg., vincristine / Generic mfg.
Enrollment change: Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma (clinicaltrials.gov) - Mar 6, 2013 P=N/A, N=66, Active, not recruiting, Active, not recruiting --> Terminated N=50 --> 66
|